Dan Loeb’s Third Point acquired approximately 85,000 Bausch + Lomb shares worth about $1.4 million as of June 30, according to the filing.
Bausch + Lomb stock drops 10% following sudden CEO departure, despite raising full-year 2026 EBITDA guidance.
Two ophthalmic candidates will now head to their next clinical stages of development in dry eye and ocular pain, respectively.
This is the newest page. Registered accounts read further back.